FindTrial
Sign In

veltuzumab

BIOLOGICAL7 trials

Sponsors

Gilead Sciences, Beth Christian, Weill Medical College of Cornell University, Takeda

Conditions

Aggressive NHLAutoimmune Thrombocytopenic PurpuraCLLDiffuse Large B-cell LymphomaFollicular LymphomaLeukemia, B-Cell, ChronicLeukemia, Lymphocytic, ChronicLeukemia, Prolymphocytic

Phase 1

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
CompletedNCT00546793
Gilead SciencesCLL, Leukemia, B-Cell, Chronic, Leukemia, Lymphocytic, Chronic +15
Start: 2008-01-31End: 2013-03-31Updated: 2021-08-16
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
TerminatedNCT00547066
Gilead SciencesAutoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune, Purpura, Thrombocytopenic, Idiopathic
Start: 2007-11-30End: 2011-11-30Updated: 2021-08-16
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
CompletedNCT00596804
Gilead SciencesLymphoma, Diffuse, Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic, Non-Hodgkin's Lymphoma
Start: 2004-03-31End: 2007-11-30Updated: 2021-08-18
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
CompletedNCT00989586
Beth ChristianLymphoma
Start: 2009-09-30End: 2015-09-30Updated: 2017-02-06
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
WithdrawnNCT01101581
Gilead SciencesAggressive NHL, Diffuse Large B-cell Lymphoma, NHL +1
Start: 2010-05-31End: 2017-03-31Updated: 2021-08-18
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
TerminatedNCT01147393
Weill Medical College of Cornell UniversityFollicular Lymphoma
Start: 2010-10-31End: 2015-07-31Updated: 2018-02-22

Phase 2

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
TerminatedNCT01390545
TakedaRheumatoid Arthritis
Start: 2011-08-31End: 2012-10-31Target: 300Updated: 2016-04-13

Related Papers

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
Haematologica2016-08-119 citations
Low‐dose anti‐<scp>CD</scp>20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
British Journal of Haematology2013-07-0626 citations
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
2010-12-2040 citations